Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
about
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaAdjuvant therapy for pancreas cancer in an era of value based cancer careEvolution and dynamics of pancreatic cancer progressionSelection criteria in resectable pancreatic cancer: a biological and morphological approachAcquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic ChemotherapyPancreatic biomarkers: could they be the answer?The complex landscape of pancreatic cancer metabolismRole of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers.Ploidy and DNA index as prognostic factors in resected pancreatic ductal adenocarcinoma - a review of the literature.Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective studyERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancerGenomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic StratificationThe evolution of tumor metastasis during clonal expansion with alterations in metastasis driver genesSafety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL.Neoadjuvant treatment for resectable pancreatic adenocarcinoma.Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinomaSmad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cellsSerum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpointMaximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer.Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.Germline mutations in Japanese familial pancreatic cancer patients.Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.Prognostic factors related with survival in patients with pancreatic adenocarcinomaGenome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.
P2860
Q26739910-FEA79BEA-3DD7-4D9F-A845-DA76FA5276ADQ26775916-5EC2C432-EBA7-40C1-A89A-9759212D016BQ26849671-FF8E7247-CB63-4D73-BE8C-00E55966F245Q26859742-811200B0-FF73-423D-94C2-A7D232BB9E13Q30376511-3518392F-5861-4D2E-A2E9-003A2B40C65AQ33566753-4A0637F0-A703-4EDC-9AF1-4C7792D738DAQ33624574-FA5FACFA-2A9F-47F3-914F-4CD43FCADE1EQ33750803-39D936B0-069B-4FF9-A643-07939CA2A19AQ33755454-57F5058E-9530-46AB-A3F3-BB15AAEA3839Q33801371-63CD8903-A64D-41B5-9B52-88A84038DA9FQ33827703-A29B9184-2AE4-4AAF-8482-3E5BDB10FD91Q33982773-CA69B056-EB53-4364-B251-C782D9384D63Q34067863-8589A7D8-AC8B-40B2-A917-CE15B0322EECQ34344060-E87EBE41-939A-4D17-8805-532FB5643753Q34990040-9201E3BE-7073-4684-9CF5-B570C9DC8208Q35080923-F8051BBF-EFD7-440A-844C-61DFA1743C75Q35250650-56C2CFED-96A1-4F81-B080-26FBDF65A864Q35556136-513432EF-9261-424D-8828-431F2A39CB23Q35578938-261C66E8-992A-4091-8B1D-98F3D24241B2Q35671422-66FD536C-ACB9-4E15-A6C7-1209BC5E7A2FQ35834208-B0E632E7-D981-4130-82AF-2FB5606BA6E3Q36187546-B4F38BD2-13D6-4E3A-A8FE-F7132ED53ED4Q36227108-5159B226-03E7-4E32-AE4F-257CF2CB35A9Q36329393-D8DD2F69-EF39-47B4-A6FA-944753C572E5Q36453968-EB2C39B4-2367-42B3-AE70-F0E08F4DA89CQ36526141-32838AFF-62E0-488A-AF43-E1CE0E7E5F76Q36707119-5B874A3C-33BB-41C2-A7CD-6699CE374A8BQ36782384-74B227D3-77D1-427F-B8F2-524C0565773DQ36825201-ABACB396-E7EB-480B-A0FE-7A8B54A10F4AQ36905807-604847A1-E6DE-4371-B15A-F6870D45634BQ36993625-45C8C95A-0D29-468B-99C0-2B98ADF87108Q37030917-BC004943-4F70-4BED-ADBB-BAF0BD99E39FQ37109795-9F84875E-EC69-4C4E-8343-6E65659D0EDCQ37206394-742E04B2-AB62-4E94-BB3C-48B7C97CB7FFQ37618295-68C84D69-0D33-4D12-A8AC-0BFC19B6DE91Q37687547-5FDAAA02-E452-440A-A1E8-974BAF8AD86CQ37725506-892436C1-AAB6-4FAD-A9C5-D1D736744332Q38242807-DE577411-1E0B-4072-BB3A-132311D8C83BQ38693071-F231A9A7-F96E-464D-BD6D-17CD0945B5A3Q38815842-2D9ED638-766A-4CD0-94F0-A2911F7FCBB2
P2860
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Immunohistochemically detected ...... resectable pancreatic cancer.
@en
Immunohistochemically detected ...... resectable pancreatic cancer.
@nl
type
label
Immunohistochemically detected ...... resectable pancreatic cancer.
@en
Immunohistochemically detected ...... resectable pancreatic cancer.
@nl
prefLabel
Immunohistochemically detected ...... resectable pancreatic cancer.
@en
Immunohistochemically detected ...... resectable pancreatic cancer.
@nl
P2093
P1433
P1476
Immunohistochemically detected ...... resectable pancreatic cancer.
@en
P2093
Keiichi Okano
Minoru Oshima
Reiji Haba
Shinichi Yachida
Shinobu Muraki
Takashi Maeba
Yasuyuki Suzuki
P304
P356
10.1097/SLA.0B013E3182827A65
P407
P577
2013-08-01T00:00:00Z